Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Videos

Clinical Outcomes With Early vs Late Ra-223 for Patients With Metastatic CRPC
Videos
Clinical Outcomes With Early vs Late Ra-223 for Patients With Metastatic CRPC
04/23/2021
Richard Lee-Ying, MD, discusses clinical outcomes of patients with metastatic castrate resistant prostate cancer when Ra-223 is used early vs late in the treatment sequence.
Richard Lee-Ying, MD, discusses clinical outcomes of patients with metastatic castrate resistant prostate cancer when Ra-223 is used early vs late in the treatment sequence.
Richard Lee-Ying, MD, discusses...
04/23/2021
Journal of Clinical Pathways
Prostate Genetic Testing Station Increases Patient Access to Genetic Testing and Counseling
Videos
Prostate Genetic Testing Station Increases Patient Access to Genetic Testing and Counseling
04/21/2021
Barry Tong, CGC, MS, MPH, discusses a study evaluating the effectiveness of a prostate Genetic Testing Station at UCSF and compared these outcomes to those of a previously implemented take-home method.
Barry Tong, CGC, MS, MPH, discusses a study evaluating the effectiveness of a prostate Genetic Testing Station at UCSF and compared these outcomes to those of a previously implemented take-home method.
Barry Tong, CGC, MS, MPH,...
04/21/2021
Journal of Clinical Pathways
Real-World Use of Cabozantinib Plus Direct Oral Anticoagulants in RCC
Videos
Real-World Use of Cabozantinib Plus Direct Oral Anticoagulants in RCC
04/21/2021
04/21/2021
Journal of Clinical Pathways
Maintenance Olaparib Demonstrates Long-Term Benefit in BRCA-Mutated Ovarian Cancer
Videos
Maintenance Olaparib Demonstrates Long-Term Benefit in BRCA-Mutated Ovarian Cancer
04/21/2021
04/21/2021
Journal of Clinical Pathways
Out-of-Pocket Costs of Apixaban vs Enoxaparin for VTE in Patients With Gynecologic Cancers
Videos
Out-of-Pocket Costs of Apixaban vs Enoxaparin for VTE in Patients With Gynecologic Cancers
04/21/2021
04/21/2021
Journal of Clinical Pathways
Medicare Reimbursement Trends for Gynecologic and Urologic Procedures
Videos
Medicare Reimbursement Trends for Gynecologic and Urologic Procedures
03/30/2021
Sandeep Voleti, BS, discusses a study evaluating monetary trends in Medicare reimbursement for radical hysterectomy and prostatectomy procedures between 2010 and 2019 and comparing these to minimally invasive approaches.
Sandeep Voleti, BS, discusses a study evaluating monetary trends in Medicare reimbursement for radical hysterectomy and prostatectomy procedures between 2010 and 2019 and comparing these to minimally invasive approaches.
Sandeep Voleti, BS, discusses a...
03/30/2021
Journal of Clinical Pathways
Stroke Program at Northwestern Medicine Central DuPage Hospital
Videos
Stroke Program at Northwestern Medicine Central DuPage Hospital
03/26/2021
03/26/2021
Journal of Clinical Pathways
Enfortumab Vedotin vs Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma
Videos
Enfortumab Vedotin vs Chemotherapy for Locally Advanced or Metastatic Urothelial Carcinoma
03/23/2021
03/23/2021
Journal of Clinical Pathways
Cardiovascular Clinical Pathways Program at New Century Health
Videos
Cardiovascular Clinical Pathways Program at New Century Health
03/19/2021
03/19/2021
Journal of Clinical Pathways
JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Popular Articles

Research in Review
Systemic Therapy Use Growing Among Elderly Patients With Head and Neck Cancer
08/12/2016
JCP Editors
Despite conflicting prospective evidence, most elderly patients with locoregionally advanced head and neck cancer treated with definitive radiotherapy also receive systemic therapy, according to results from a study...
Despite conflicting prospective evidence, most elderly patients with locoregionally advanced head and neck cancer treated with definitive radiotherapy also receive systemic therapy, according to results from a study...
...
08/12/2016
Journal of Clinical Pathways
Quiz
Friday Morning Quiz – Week of July 25–31
07/29/2016
JCP Editors
A recent study of vemurafenib, an immunotherapy drug already approved for use in patients with BRAF-positive melanoma, also showed promising anti-tumor activity in which of the following cancer...
A recent study of vemurafenib, an immunotherapy drug already approved for use in patients with BRAF-positive melanoma, also showed promising anti-tumor activity in which of the following cancer...
A...
07/29/2016
Journal of Clinical Pathways
Research in Review
Shortened Radiotherapy for Breast Cancer Supported in Study
06/22/2016
JCP Editors
A shortened course of radiotherapy for patients with early stage breast cancer may actually produce slightly better outcomes than the conventional protocol, according to the results of a randomized clinical...
A shortened course of radiotherapy for patients with early stage breast cancer may actually produce slightly better outcomes than the conventional protocol, according to the results of a randomized clinical...
A...
06/22/2016
Journal of Clinical Pathways
Research Reports
Cost-Effectiveness of Afatinib Versus Erlotinib in the First-line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With EGFR Exon 19 Deletion Mutations
05/06/2016
Jonathan Graham, BS
Stephanie Earnshaw, PhD
Jonathan Lim, BS, MS, MSc
Rakesh Luthra, MS
Rohit Borker, PhD
Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...
Abstract: A decision model was developed to compare the cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non–small cell lung cancer (NSCLC) with epidermal growth...
...
05/06/2016
Journal of Clinical Pathways
Quiz
Friday Morning Quiz - Week of April 16-22
04/21/2016
JCP Editors
In a head-to-head trial comparing two prominent treatments for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), which drug came out ahead? A. afatinib B. gefitinib C. erlotinib D....
In a head-to-head trial comparing two prominent treatments for patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), which drug came out ahead? A. afatinib B. gefitinib C. erlotinib D....
In a...
04/21/2016
Journal of Clinical Pathways

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement